In 10 children with cystic fibrosis and persisting steatorrhoea, supplementation with taurine (30-40 mg/kg/day) was given for two months as an adjunct to the usual pancreatic enzyme treatment. A three day fat and energy balance was performed in patients with cystic fibrosis, before and after the supplementation, and in seven healthy controls who did not receive taurine.
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Faecal fat was measured by a gravimetric method and stool energy was determined using a bomb calorimeter. Patients with cystic fibrosis, before and after taurine, and healthy controls received the same fat and energy intake (calculated by a dietitian). In patients with cystic fibrosis taurine did not produce any improvement of steatorrhoea (mean (SD) faecal fat 8-7 (3.3) v 11-2 (7.0) g/day, respectively before and after the supplementation), of faecal energy loss (0-978 (0.468) v 1-133 (0.539) MJ/day), of faecal fat expressed as percent of fat intake (13-4 (5.6) v 15-1 (9-8)%), and of faecal energy expressed as percent of energy intake (9.9 (3.6) v 11-2 (5-7)%). Healthy controls had significant lower fat (3.5 (2.3) g/day) and energy 0-576 (0.355) MJ/day faecal losses.
In conclusion, taurine failed to decrease significantly fat and energy losses. Our study does not support the use of taurine supplementation in the nutritional management of cystic fibrosis. All patients were supplemented with an enteric coated enzyme preparation of pancreatin (Pancrease, Cilag). The number of capsules, ranging from a minimum of six to a maximum of 20 a day in the whole study group, remained the same during the study.
DESIGN OF THE STUDY
The experiment was performed on an ambulatory basis and the patients, who were well at the time of the study, remained clinically stable for the whole period of supplementation. Taurine (0-Due, Nativelle) was administered for two months twice daily at a dose of 30-40 mg/kg/day as suggested by Darling et al.4 Before and two months after starting the supplementation a fat and energy balance study was performed in each patient. Weighed food intake was recorded for a period of six days by a daily diary and a dietitian controlled the records to check for errors. The weighed food intake was analysed using food composition data.9
Effect oftaurine supplementation onfat and energy absorption in cysticfibrosis Gross energy intakes were estimated by multiplying the intakes of fat (39-3 kJ/g), protein (as nitrogenx6-25; 23-6 kJ/g), and carbohydrate (17-6 kJ/g) by their respective heat of combustion values.'0 All stools, collected in the final three days of the record period, were kept in polyethylene bags and immediately frozen. Coal tablets were used as charcoal markers between the start and the end of the collection period.
All the patients were cooperative and no gross errors were found in the daily diary or the procedure for stool collection. During the collection periods the fat content of the diet was not different from the patients' usual diet (about 3 g/kg/day).
A fat and energy balance study was also performed in seven healthy children, with a mean age of 10 years (range [6] [7] [8] [9] [10] [11] [12] Energy was determined on dried stools using a ballistic bomb calorimeter (Gallenkamp) as reported elsewhere. 2 Results are given as faecal fat (g/day), faecal energy (MJ/day), and % of fat intake and % of gross energy intake. All the values are expressed as mean (1SD).
The significance of the difference between two arithmetic means was evaluated with the paired and unpaired Student's t test and differences between means were considered significant where p<0 05.
Results
Taurine supplementation was well tolerated and no side effects were noted. All patients complied with the treatment, as written records of the daily consumption of taurine and of pancreatic extracts were reported by the parents.
In patients with cystic fibrosis daily fat intake was not different in the two periods of stool collection (before taurine, 70 5 (22 5) g/day; after taurine, 76-3 (21 3) g/day). In healthy controls, fat intake was 79-4 (27-8) g/day.
In patients with cystic fibrosis the weight of It group.bmj.com on January 21, 2018 -Published by http://adc.bmj.com/ Downloaded from fibrosis the faecal fat expressed as % of fat intake was 13-4 (5-6)% before taurine and 15-1 (9-8)% after taurine (the difference was not significant). In controls the faecal fat expressed as % of fat intake was lower than in patients with cystic fibrosis (4-3 (2 2)%; p<O001).
Gross energy intake was 10-11 (2-691) MJ/ day and 10-442 (2-575) MJ/day in patients with cystic fibrosis, respectively before and after taurine; in controls subjects it was 10-065 (2-215) MJ/day.
In patients with cystic fibrosis, faecal energy loss was not different in the two periods (before taurine, 0-978 (0-468) MJ/day; after taurine, 25. As illustrated in fig 4, in patients with cystic fibrosis faecal energy expressed as % of gross energy intake did not change before and after taurine administration (respectively, 9-9 (3 6)% v 11 -2 (5 7)%; the difference was not significant). Healthy controls had a faecal energy expressed as % of gross energy intake significantly lower than patients with cystic fibrosis (5 5 (3 0); p=O 009).
Discussion
To our knowledge this represents the first longitudinal study that measures both faecal lipid and energy losses in patients with cystic fibrosis before and after taurine supplementation. The main consequence of pancreatic insufficiency in cystic fibrosis is the failure to digest and absorb some components of the diet. Fat and nitrogen malabsorption are common in these patients and the faecal energy losses reflect the nutrients' malabsorption.
As enzyme replacement diminishes but does not normalise the amount of fat and nitrogen lost in stools, the use of other drugs that can improve fat malabsorption has been suggested in cystic fibrosis."3 Nevertheless, a definitive resolution of the symptoms due to steatorrhoea is rarely achieved. In this study we were unable to demonstrate that taurine leads to an improvement in the absorption of fat and energy in 10 children with cystic fibrosis who had persisting fat malabsorption despite appropriate enzyme treatment. These findings contrast with most of the reports about the use of taurine in cystic fibrosis,"5 but are similar to the conclusions of other studies, which did not support the therapeutic use of taurine in the nutritional management of cystic fibrosis. 6 7 The disagreement in the results of the studies on taurine supplementation in cystic fibrosis could be related to differences in the characteristics of the study population. People who suggest the use of taurine in cystic fibrosis recommend it particularly in patients with a significant degree ofsteatorrhoea, but our results, like those by Thompson et al,6 7 do not reveal any improvement in fat and energy absorption, even in cases with a low baseline high fat and energy losses.
The dose of taurine and the length of the supplementation cannot represent a bias: in our study taurine was given at the same dose and for the same period as in another study that concluded that taurine was effective in cystic fibrosis.5 However, Thompson et al showed that the glycine:taurine conjugates ratio is remarkably sensitive to even relatively small doses of taurine. 7 Recently, another group has published data regarding the energy and fat content of stools in patients with cystic fibrosis. 4 Similar values of both faecal fat and faecal energy have been found in our patients.
In healthy patients we found a slightly higher fat and energy faecal excretion than those Faecal energy does not represent only malabsorbed energy: in addition to maldigested and unabsorbed dietary residues, faecal energy losses can be due in part to colonic bacteria and to products from cellular lysis, which represents up to 30% of the faecal energy. 14 In our study, fat absorption was estimated in terms of steatorrhoea and of the percentage of dietary fat intake, which had been strictly checked by a dietitian. In the previous studies no detailed data about the dietary intake of fats are given: the variation of fat intake itself may account for changes in faecal fat loss unrelated to fat absorption. Furthermore, in one of these studies the authors give results in terms of 'steatorrhoea', that is quite different from the percent of fat intake.4
In cystic fibrosis some evidence exists for impairment of fat absorption, which is distinct from the maldigestion of fat consequent on absence of pancreatic lipase. Some steatorrhoea may persist with enteric coated enzyme preparations, even when optimal intraluminal pH for exogenous lipase is achieved by the use of cimetidine and sodium bicarbonate.'3 A reduction in the bile acids pool resulting from decreased ileal reabsorption may be a partial explanation. 2 The efficacy of taurine in cystic fibrosis is based on the assumption that this amino acid provides the necessary substrate for the synthesis of taurine-conjugated bile acids, which in turn, could improve the micellar solubilisation of lypolitic products.'6 Our patients had no liver and biliary tract disease. Nevertheless, as ileal mucosal bile acids malabsorption has been postulated in cystic fibrosis,'7 we cannot definitely state that our patients did not benefit from taurine supplementation because taurineconjugated bile acids are less efficiently absorbed across the ileum.
In our study a variability in the response to supplementation appears in some individual patients. An explanation for this and for the considerable variability ofthe response to taurine supplementation among the various groups is the great heterogeneity of fat malabsorption in cystic fibrosis, which can be due both to lipase deficiency and to decreased solubility of bile acids micelles in the unstirred water layer. In this view the hypothesis of the association between taurine deficiency and biliary abnormalities in some patients with cystic fibrosis appears interesting. This finding supports the conclusion that taurine could be helpful only in selected patients, particularly if fat malabsorption is more related to the bile acid component than to the exocrine pancreatic insufficiency itself.
Taurine supplementation is also a controversial issue in low birthweight infants, who usually present with a low fat absorption. 8 
